SEARCH

SEARCH BY CITATION

References

  • 1
    Santos-de-Unamuno C, Llorente-San-Martín MA, Carandell E et al. Lugar de Atención, Etiologia y tratamiento de las neumonías adquiridas en la comunidad de Palma de Mallorca. Med Clin (Barc) 1998; 110: 290294.
  • 2
    Almirall J, Bolíbar I, Vidal J et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000; 15: 757763.
  • 3
    Aguirre I, Bilbao JJ, Olarreaga M et al. Neumonias adquiridas en la Comunidad en Andoain. Aten Primaria 1993; 12: 359362.
  • 4
    Zalacaín R, Gómez A. Tratamiento de la neumonía adquirida en la comunidad. Papel de las cefalosporinas orales. Med Clin Monogr (Barc) 2006; 7: 2329.
  • 5
    Niederman MS, Mandell LA, Anzueto A et al. ; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 17301754.
  • 6
    Shah PB, Giudice JC, Griesback R Jr, Morley TF, Vasoya A. The newer guidelines for the management of community-acquired pneumonia. J Am Osteopath Assoc 2004; 104: 521526.
  • 7
    Abrahamian FM, Deblieux PM, Emerman CL et al. Health care-associated pneumonia: identification and initial management in the ED. Am J Emerg Med 2008; 26 (6 suppl): 111.
  • 8
    Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 38543862.
  • 9
  • 10
    Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331344.
  • 11
    Gobernado M, Sanz-Rodríguez C, Villanueva R, Torroba L, Redondo E, González-Esteban J. Actividad in vitro de ertapenem frente a cepas bacterianas aisladas en 69 centros médicos españoles (Estudio E-test). Rev Esp Quimioter 2007; 20: 395408.
  • 12
    Boselli E, Breilh D, Saux MC, Gordien JB, Allaouchiche B. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med 2006; 32: 20592062.
  • 13
    Vetter N, Cambronero-Hernandez E, Rohlf J et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002; 24: 17701785.
  • 14
    Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A; Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002; 34: 10761083.
  • 15
    Ortiz-Ruiz G, Vetter N, Isaacs R, Carides A, Woods GL, Friedland I. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother 2004; 53 (suppl 2): ii59ii66.
  • 16
    Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243250.
  • 17
    Woods GL, Isaacs RD, McCarroll KA, Friedland IR. Ertapenem therapy for community-acquired pneumonia in the elderly. J Am Geriatr Soc 2003; 51: 15261532.
  • 18
    Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 14051433.